Global Chronic Liver Diseases Therapeutics Market– Driver
Increasing cancer cases such as liver cancer
Increasing cancer cases such as liver cancer is expected to propel growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, according to an article published in the World Health Organization, in February 2022, the age-standardized point prevalence and annual incidence rates of cancer were 246.6 and 14.9 in 2021, which increased by 7.4% and 8.2% from 1990, respectively. Cancer is a leading cause of death worldwide, accounting for nearly 10 billion deaths in 2020. As per the national orgniasation of rare disorders reported, the incidence of liver is estimated approximately 1 per 1,000,000 people. About 300 cases of chordoma are diagnosed in the U.S. each year.
Increasing research & development activities for the treatment of chronic liver diseases
Increasing research & development activities for the treatment of chronic liver diseases is expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in January 2022, Madrigal Pharmaceuticals, Inc. announced positive top line clinical data from the placebo-controlled, double-blind portion of its phase 3 MAESTRO-NAFLD (non-alcoholic fatty liver disease) safety study of resmetirom.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients